Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Gross Margin (2016 - 2017)

Historic Gross Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Q2 2017 value amounting to 4100.0%.

  • Soleno Therapeutics' Gross Margin fell 16500000.0% to 4100.0% in Q2 2017 from the same period last year, while for Jun 2017 it was 0.74%, marking a year-over-year decrease of 112900.0%. This contributed to the annual value of 4.03% for FY2016, which is 459800.0% down from last year.
  • As of Q2 2017, Soleno Therapeutics' Gross Margin stood at 4100.0%, which was down 16500000.0% from 21.13% recorded in Q1 2017.
  • Over the past 5 years, Soleno Therapeutics' Gross Margin peaked at 77.33% during Q3 2015, and registered a low of 4100.0% during Q2 2017.
  • In the last 3 years, Soleno Therapeutics' Gross Margin had a median value of 7.52% in 2015 and averaged 636.51%.
  • Over the last 5 years, Soleno Therapeutics' Gross Margin had its largest YoY gain of 279600bps in 2016, and its largest YoY loss of -25273200bps in 2016.
  • Soleno Therapeutics' Gross Margin (Quarter) stood at 6.3% in 2015, then skyrocketed by 444bps to 21.66% in 2016, then plummeted by -19025bps to 4100.0% in 2017.
  • Its Gross Margin was 4100.0% in Q2 2017, compared to 21.13% in Q1 2017 and 21.66% in Q4 2016.